Featured Articles

TAG’s 2019 Pipeline Report: The Latest in HIV and HCV R&D

Treatment Action Group | July 2019

Changes in drug interaction profiles for first-line HIV therapy over the 20 years of the Liverpool Drug Interaction website

Department of Pharmacology & Therapeutics, University of Liverpool

Proportion of serious drug interactions dropping on Liverpool antiretroviral website

20th International Workshop on Clinical Pharmacology of HIV, Hepatitis & Other Antiviral Drugs. May 14-16, 2019. Noordwijk, the Netherlands

Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States

aidsinfo | December 2018

Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV

AIDSinfo | October 25, 2018

Meta-analysis of the risk of Grade 3/4 or serious clinical adverse events in 12 randomised trials of PrEP
HIV Drug Therapy, Glasgow 2018, October 28-31, 2018, Glasgow
Department of Health and Human Services Adults and Adolescents Antiretroviral Guidelines Panel* Classifies a Fixed-Dose Combination Product of Bictegravir/Tenofovir Alafenamide/Emtricitabine as One of the Recommended Initial Regimens for Most People with HIV
AIDSinfo |  March 27, 2018
Hepatitis C Treatments Viekira Pak and Technivie: Drug Safety Communication - Risk of Serious Liver Injury
NASTAD Release: ADAP Formulary Database
HIV/AIDS Update- Prezista (darunavir) labeling changes
The 17th Annual HIV Drug Guide
Positively Aware, Test Positive Aware Network
   
News Updates

FDA warns patients and health care professionals about rare instances of serious liver injury or failure with certain hepatitis C treatments in some patients with advanced liver disease

FDA | August 28, 2019

ViiV Healthcare reports positive phase III study results of investigational, long-acting, injectable HIV-treatment regimen administered every two months

GSK | August 22, 2019

Extensive Drug Resistance Has Become Rare Among People With HIV

POZ | August 19, 2019

FDA panel backs Gilead's HIV prevention drug for certain population

Reuters | August 7, 2019

BIKTARVY: recent changes to labeling

FDA | August 6, 2019

ViiV Healthcare Submits Regulatory Application to European Medicines Agency for Investigational ... 

Yahoo Finance | July 29, 2019

WHO Recommends Antiretroviral Drug Dolutegravir As Preferred HIV Treatment, Including For ... 

Kaiser Family Foundation | July 23, 2019

Folic acid reduces risk of neural tube defects linked to HIV drug dolutegravir

EurekAlert | July 23, 2019

Efficacy and safety of dolutegravir–rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies

The Lancet | July 12, 2019

Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV 

aidsinfo | July 10, 2019

Merck Highlights Commitment to HIV Research with Presentations for Investigational Anti-HIV Agent MK-8591 at IAS 2019

BioSpace | July 10, 2019

ViiV Healthcare announces phase III study meets primary endpoint, demonstrating the ability to control HIV-1 with a 2-drug regimen of dolutegravir plus lamivudine in virally suppressed patients switching from a TAF-containing, 3-drug regimen

ViiV Healthcare | July 10, 2019

GSK's Dovato suppresses AIDS virus at same levels of three-drug regimen 

Reuters | July 10, 2019

Gilead and Lyndra Team Up to Develop Long-Acting HIV Therapies

BioSpace | July 9, 2019

ViiV Healthcare announces start of first-ever study to identify and evaluate approaches to implementing its once-monthly injectable HIV treatment in clinical practice

ViiV Healthcare | July 8, 2019

TRUVADA: Important Updates to the REMS

FDA: HIV Email Updates | July 1, 2019

Long-Acting Antiretrovirals for Treatment 

NASTAD | June 26, 2019

HIV Updates: BIKTARVY label revisions

HIV drug cabotegravir not associated with weight gain

Healio | June 8, 2019

AIDS groups criticize Express Scripts for excluding several HIV medicines

STAT | June 6, 2019

National Ryan White HIV/AIDS Program (RWHAP) Part B and AIDS Drug Assistance Program (ADAP) Monitoring Project: 2019 Annual Report

NASTAD | June 6, 2019

Other than dolutegravir, no antiretroviral interactions with valproic acid in 134 people
20th International Workshop on Clinical Pharmacology of HIV, Hepatitis & Other Antiviral Drugs. May 14-16, 2019. Noordwijk, the Netherlands

Phase 1 results show safety and once-daily potential of new HIV maturation inhibitor

20th International Workshop on Clinical Pharmacology of HIV, Hepatitis & Other Antiviral Drugs. May 14-16, 2019. Noordwijk, the Netherlands

Management of antiretrovirals in Seniors - The importance of assisted treatment for adherence to treatment

20th International Workshop on Clinical Pharmacology of HIV, Hepatitis & Other Antiviral Drugs. May 14-16, 2019. Noordwijk, the Netherlands

One third of French HIV group uses illicit drugs, often risking antiretroviral interactions

20th International Workshop on Clinical Pharmacology of HIV, Hepatitis & Other Antiviral Drugs. May 14-16, 2019. Noordwijk, the Netherlands

Baseline genotype testing at HIV diagnosis not cost-effective

Healio | May 13, 2019

Gilead to Donate Up to 2.4M Bottles of HIV Prevention Pills Each Year in the U.S.

POZ | May 10, 2019

NIH Trial Evaluates Long-acting HIV Medication Unable to Adhere to Strict Daily Regimens

NIH | May 9, 2019

Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial

The Lancet | May 5, 2019

ViiV Healthcare seeks FDA approval for long-term injectable HIV treatment

WRAL Tech Wire | April 29, 2019

MSM at Highest Risk for HIV Acquisition Express Greatest Interest and Preference for Injectable Antiretroviral PrEP Compared to Daily, Oral Medication

AIDS Behav. 2018 Apr;22(4):1158-1164. doi: 10.1007/s10461-017-1972-6

Updates New ARTs/ New ART Data - CROI including Bictegravir, Dolutegravir+Rilpivirine, Dolutegravir+3TC, Doravirine; Fostemsavir & MK-8591

NATAP | April 10, 2019

NATAP: HIV-Drug Resistance Testing/DHHS Guidelines

Last Updated: October 25, 2018

ViiV Healthcare Announces CHMP Positive Opinion for DOVATO® (DOLUTEGRAVIR/LAMIVUDINE) as a Once-Daily, Single-Pill, Two-Drug Reimen for the Treatment of HIV Infection

ViiV | April 26, 2019

New Rule at Centers for Medicare and Medicaid Helps Lower Costs of Meds

POZ | April 23, 2019

Special thanks to The AIDS Institute for leading the charge on this important issue

Expanded Access - Pre-Approval Access to Rilpivirine Long Acting (RPV LA) Injectable Suspension for the Treatment of a Participant With Human Immunodeficiency Virus (HIV)-1 Infection

NATAP | April 18, 2019

FDA Has Approved New Two-Drug Regimen to Treat People with HIV

Healthline | April 15, 2019

Janssen Presents New Data from First Phase 3 Trial of a Single-Tablet Regimen in a Rapid Initiation Model of Care Demonstrating Safety and Efficacy with SYMTUZA® through 48 Weeks

Janssen | April 11, 2019

FDA approves first two-drug complete regimen for HIV-infected patients who have never received antiretroviral treatment

FDA | April 8, 2019

Gilead Announces New Grant Programs Supporting Investigator-Sponsored Research in Liver Diseases

Market Watch |  Apr 9, 2019

Pharma giant profits from HIV treatment funded by taxpayers and patented by the government

Washington Post | March 26, 2019

Gilead's Asegua Therapeutics selected to partner with health department for hepatitis C drug subscription model

Gilead | March 26, 2019

Long-acting injectable treatment maintains viral suppression

aidsmap | March 8, 2019

Factors associated with therapeutic failure of 2-drug regimens, DAT’AIDS cohort: Two-antiretroviral maintenance failure--raltegravir regimens seem most vulnerable

Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7, 2019, Seattle

Integrase inhibitor treatment leads to greater weight gain

aidsmap | March 7, 2019

ViiV Healthcare Presents Positive, 48-Week Data from Two Pivotal Phase III Studies Showing Long-Acting, Injectable Two-Drug Regimen of Cabotegravir and Rilpivirine Has Similar Efficacy to Daily, Three-Drug Oral Treatment in Adults Living with HIV-1 Infection

ViiV | March 7, 2019

HIV-1 escape in the central nervous system on elvitegravir-based antiretroviral therapy

AIDS: March 1, 2019

Gilead Announces Topline Data From Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)

Gilead | February 11, 2019

Acyclovir labeling now includes details for treating premature infants infected with herpes virus

NIH | February 8, 2019

FDA Hepatitis Update- VEMLIDY labeling revised (renal information)

FDA | February 6, 2019

U.S. FDA Accepts sNDAs for PIFELTRO™ (doravirine) and DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate)
Merck | January 22, 2019

Pharm To Exam Table – Candida glabrata Urinary Tract Infections

University of Nebraska Medical Center | December 21, 2018

Note from Dr. Reznik – This information is valuable for oral infections with Candida glabrata

HIV EMAIL UPDATES

FDA | December 11, 2018

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

The Lancet | November 9, 2018

Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial

PLoS Med. 2018 Nov 8;15(11):e1002690. doi: 10.1371/journal.pmed.1002690. eCollection 2018 Nov

FDA HIV Update: GENVOYA, STRIBILD, and TYBOST Pregnancy Label

FDA | November 7, 2018

Novel antibiotic shows promise in treatment of uncomplicated gonorrhea

NIH | November 7, 2018

NASTAD Announces the Release of PrEPcost.org

NASTAD | November 6, 2018

Development of an End-user Informed Tenofovir Alafenamide (TAF) Implant for Long-acting (LA)-HIV Pre-exposure Prophylaxis (PrEP)

NATAP | November 6, 2018

Transgender women taking PrEP have lower levels of PrEP drugs, especially in rectal tissues, than ...

aidsmap | November 2018

Prolonged HIV suppression is possible using ibalizumab, analysis of highly drug-resistant patients ...

aidsmap | November 2, 2018

Dolutegravir or lower-dose efavirenz equally effective, but less resistance with dolutegravir

aidsmap | November 1, 2018

FDA HIV Update- ODEFSEY/COMPLERA: Pregnancy Label Updates

FDA | October 31, 2018

ViiV Healthcare reports positive 48-week results for second phase III study for novel, long-acting, injectable HIV-treatment regimen

HIV Drug Therapy, Glasgow 2018, October 28-31, 2018, Glasgow

Two Thirds Reach Sub-50 Viral Load Through 48 Weeks With Ibalizumab

HIV Drug Therapy, Glasgow 2018, October 28-31, 2018, Glasgow

Polypharmacy in One Third of Big HIV Cohort vs One Fifth of Non-HIV Group
HIV Drug Therapy, Glasgow 2018, October 28-31, 2018, Glasgow
Good HIV Response Rate, Sustained Safety Through 96 Weeks With D/C/F/TAF
HIV Drug Therapy, Glasgow 2018, October 28-31, 2018, Glasgow

Outcomes of Patients Not Achieving Primary Endpoint From an Ibalizumba Phase 3 Trial

HIV Drug Therapy, Glasgow 2018, October 28-31, 2018, Glasgow

Bictegravir/F/TAF Noninferior to DTG Plus F/TAF at 96 Weeks: No Resistance
HIV Drug Therapy, Glasgow 2018, October 28-31, 2018, Glasgow